In vitro metabolic interaction studies: Experience of the food and drug administration

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 1, 1999, Pages 9-15

  Yuan, Rae ^a   Parmelee, Thomas ^a   Balian, John D ^a   Uppoor, Ramana S ^a   Ajayi, Funmilayo ^a   Burnett, Alfreda ^a   Lesko, Larry J ^a   Marroum, Patrick ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; 4 NITROPHENOL; ANILINE; ANTIBODY; BUFURALOL; CAFFEINE; COMPLEMENTARY DNA; COUMARIN; CYCLOSPORIN; CYTOCHROME; DESIPRAMINE; DEXTROMETHORPHAN; ENZYME; ERYTHROMYCIN; FURAFYLLINE; IMIPRAMINE; ISONIAZID; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; OMEPRAZOLE; ORPHENADRINE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SPARTEINE; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG; ZALCITABINE;

ARTICLE; DRUG ACCUMULATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; METABOLISM; MICROSOME; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; GENOTYPE; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032778908     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70048-2     Document Type: Article

References (18)

1. 1. Kudo K, Imamura T, Jitsufuchi N, Zhang XX, Tokunaga H, Nagata T. Death attributed to the toxic interaction of triazolam, amitriptyline and other psychotropic drugs. Forensic Sci Int 1997;86:35-41.
2. 2. Ferslew KE, Hagardorn AN, Harlan GC, McCormick WF. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;43:1082-5.
3. 3. Gryn J, Gordon R, Bapat A, Goldman N, Goldberg J. Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant 1993;12:217-20.
4. 4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
5. 5. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
6. 6. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1 hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994;11:921-4.
7. 7. Rowland M, Matin S. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973;1:553-67.
8. 8. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
9. 9. Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301.
10. 10. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994;4:359-62.
11. 11. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
12. 12. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276:370-9.
13. 13. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321-32.
14. 14. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994;34:1222-7.
15. 15. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-Demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275: 592-7.
16. 16. Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997;62:384-91.
17. 17. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997;73:147-71.
18. 18. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998; 55:113-22.